ARTEMIS: A Robust TNBC Evaluation fraMework to Improve Survival.
The goal of this clinical research study is to learn if the use of imaging response and molecular testing on tumors can improve response to treatment in patients with triple-negative breast cancer (TNBC) by guiding patients with chemotherapy-sensitive tumors to receive standard chemotherapy and chemotherapy-insensitive tumors to consider a clinical trial.
Disease Group: Breast
Treatment Agent: None
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: MDACC: (Institutional MoonShots Fund)
IRB Review and Approval Date: 11/09/2015
Recruitment Status: Open
Projected Accrual: 1000
Information and next steps
Breast Medical Oncology
For general questions about clinical trials: